Arrowstreet Capital Limited Partnership trimmed its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 21.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,025,693 shares of the company's stock after selling 278,297 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.50% of Cellebrite DI worth $22,596,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the company. FMR LLC raised its position in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after acquiring an additional 3,239,307 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Cellebrite DI by 11.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 111,791 shares of the company's stock valued at $1,883,000 after purchasing an additional 11,730 shares during the last quarter. Verition Fund Management LLC raised its holdings in Cellebrite DI by 20.6% during the third quarter. Verition Fund Management LLC now owns 110,259 shares of the company's stock worth $1,857,000 after purchasing an additional 18,859 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Cellebrite DI by 68.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 98,246 shares of the company's stock worth $1,654,000 after buying an additional 39,946 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at $27,000. 45.88% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages recently weighed in on CLBT. Lake Street Capital boosted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. upped their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $23.43.
View Our Latest Stock Analysis on CLBT
Cellebrite DI Trading Down 1.1 %
Shares of CLBT traded down $0.19 during mid-day trading on Tuesday, hitting $17.75. 874,622 shares of the company's stock were exchanged, compared to its average volume of 1,396,640. The firm has a market capitalization of $4.25 billion, a P/E ratio of -12.77, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30. The business's 50 day moving average is $20.06 and its two-hundred day moving average is $19.96.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
